Anavex Life Sciences (AVXL) Competitors

$3.08 0.00 (0.00%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$3.08 +0.00 (+0.16%)

As of 05/14/2026 04:10 PM Eastern

AVXL vs. QURE, MLTX, PHAR, JBIO, and CALT

Should you buy Anavex Life Sciences stock or one of its competitors? MarketBeat compares Anavex Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anavex Life Sciences include uniQure (QURE), MoonLake Immunotherapeutics (MLTX), Pharming Group (PHAR), Jade Biosciences (JBIO), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry.

How does Anavex Life Sciences compare to uniQure?

uniQure (NASDAQ:QURE) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

Anavex Life Sciences has lower revenue, but higher earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	108.71	-$198.97M	-$3.48	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

Anavex Life Sciences has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Anavex Life Sciences' return on equity of -38.76% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
Anavex Life Sciences	N/A	-38.76%	-35.01%

78.8% of uniQure shares are owned by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are owned by institutional investors. 4.8% of uniQure shares are owned by company insiders. Comparatively, 11.4% of Anavex Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, uniQure had 10 more articles in the media than Anavex Life Sciences. MarketBeat recorded 14 mentions for uniQure and 4 mentions for Anavex Life Sciences. uniQure's average media sentiment score of 0.52 beat Anavex Life Sciences' score of 0.47 indicating that uniQure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

uniQure has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

uniQure currently has a consensus target price of $42.83, suggesting a potential upside of 54.35%. Anavex Life Sciences has a consensus target price of $21.33, suggesting a potential upside of 592.64%. Given Anavex Life Sciences' higher possible upside, analysts clearly believe Anavex Life Sciences is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Anavex Life Sciences beats uniQure on 8 of the 15 factors compared between the two stocks.

How does Anavex Life Sciences compare to MoonLake Immunotherapeutics?

Anavex Life Sciences (NASDAQ:AVXL) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 11.4% of Anavex Life Sciences shares are owned by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, MoonLake Immunotherapeutics had 23 more articles in the media than Anavex Life Sciences. MarketBeat recorded 27 mentions for MoonLake Immunotherapeutics and 4 mentions for Anavex Life Sciences. MoonLake Immunotherapeutics' average media sentiment score of 0.59 beat Anavex Life Sciences' score of 0.47 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MoonLake Immunotherapeutics	7 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Anavex Life Sciences is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

Anavex Life Sciences currently has a consensus target price of $21.33, suggesting a potential upside of 592.64%. MoonLake Immunotherapeutics has a consensus target price of $23.85, suggesting a potential upside of 29.67%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Anavex Life Sciences is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38

Anavex Life Sciences' return on equity of -38.76% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-38.76%	-35.01%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Anavex Life Sciences has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

Summary

Anavex Life Sciences beats MoonLake Immunotherapeutics on 7 of the 13 factors compared between the two stocks.

How does Anavex Life Sciences compare to Pharming Group?

Anavex Life Sciences (NASDAQ:AVXL) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Anavex Life Sciences currently has a consensus target price of $21.33, suggesting a potential upside of 592.64%. Pharming Group has a consensus target price of $38.33, suggesting a potential upside of 195.78%. Given Anavex Life Sciences' higher probable upside, equities analysts clearly believe Anavex Life Sciences is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 11.4% of Anavex Life Sciences shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Pharming Group has a net margin of 3.30% compared to Anavex Life Sciences' net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-38.76%	-35.01%
Pharming Group	3.30%	4.64%	2.55%

In the previous week, Pharming Group had 6 more articles in the media than Anavex Life Sciences. MarketBeat recorded 10 mentions for Pharming Group and 4 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 0.47 beat Pharming Group's score of 0.37 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharming Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pharming Group has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A
Pharming Group	$376.13M	2.43	$2.85M	$0.16	81.00

Anavex Life Sciences has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, Pharming Group has a beta of 0.04, suggesting that its stock price is 96% less volatile than the broader market.

Summary

Pharming Group beats Anavex Life Sciences on 8 of the 13 factors compared between the two stocks.

How does Anavex Life Sciences compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Jade Biosciences presently has a consensus target price of $34.33, indicating a potential upside of 42.28%. Anavex Life Sciences has a consensus target price of $21.33, indicating a potential upside of 592.64%. Given Anavex Life Sciences' higher possible upside, analysts clearly believe Anavex Life Sciences is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Anavex Life Sciences' return on equity of -38.76% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-51.34%	-47.32%
Anavex Life Sciences	N/A	-38.76%	-35.01%

In the previous week, Jade Biosciences had 9 more articles in the media than Anavex Life Sciences. MarketBeat recorded 13 mentions for Jade Biosciences and 4 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 0.47 beat Jade Biosciences' score of -0.50 indicating that Anavex Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Jade Biosciences is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

31.6% of Anavex Life Sciences shares are held by institutional investors. 23.1% of Jade Biosciences shares are held by company insiders. Comparatively, 11.4% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Jade Biosciences has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market.

Summary

Anavex Life Sciences beats Jade Biosciences on 8 of the 14 factors compared between the two stocks.

How does Anavex Life Sciences compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Anavex Life Sciences. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 11.4% of Anavex Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Anavex Life Sciences has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Anavex Life Sciences' return on equity of -38.76% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Anavex Life Sciences	N/A	-38.76%	-35.01%

In the previous week, Anavex Life Sciences had 4 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 4 mentions for Anavex Life Sciences and 0 mentions for Calliditas Therapeutics AB (publ). Anavex Life Sciences' average media sentiment score of 0.47 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Anavex Life Sciences	Neutral

Anavex Life Sciences has a consensus target price of $21.33, indicating a potential upside of 592.64%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Anavex Life Sciences is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

Summary

Anavex Life Sciences beats Calliditas Therapeutics AB (publ) on 11 of the 15 factors compared between the two stocks.

Get Anavex Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVXL vs. The Competition

Export

Metric	Anavex Life Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$285.43M	$3.42B	$6.34B	$12.38B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-6.70	18.47	20.89	25.63
Price / Sales	N/A	294.87	549.88	76.62
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	2.80	6.93	9.93	6.97
Net Income	-$46.38M	$24.11M	$3.55B	$333.62M
7 Day Performance	-4.35%	5.89%	1.70%	1.09%
1 Month Performance	-4.94%	-0.91%	0.49%	3.08%
1 Year Performance	-63.20%	74.58%	39.41%	35.68%

Anavex Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVXL Anavex Life Sciences	1.7986 of 5 stars	$3.08 flat	$21.33 +592.6%	-62.3%	$285.43M	N/A	N/A	40	Analyst Downgrade
QURE uniQure	2.9134 of 5 stars	$20.68 +8.1%	$43.33 +109.5%	+119.4%	$1.21B	$16.10M	N/A	500	Insider Trade
MLTX MoonLake Immunotherapeutics	3.4253 of 5 stars	$17.56 +5.0%	$23.08 +31.4%	-50.3%	$1.20B	N/A	N/A	2	Trending News Earnings Report Analyst Forecast Analyst Revision
PHAR Pharming Group	3.9385 of 5 stars	$16.39 -3.5%	$38.33 +133.9%	+41.6%	$1.20B	$376.13M	1,639.00	280	Earnings Report Analyst Downgrade Analyst Revision
JBIO Jade Biosciences	2.258 of 5 stars	$24.52 +1.2%	$31.17 +27.1%	N/A	$1.19B	N/A	N/A	20	Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVXL) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anavex Life Sciences (AVXL) Competitors

AVXL vs. QURE, MLTX, PHAR, JBIO, and CALT

How does Anavex Life Sciences compare to uniQure?

Summary

How does Anavex Life Sciences compare to MoonLake Immunotherapeutics?

Summary

How does Anavex Life Sciences compare to Pharming Group?

Summary

How does Anavex Life Sciences compare to Jade Biosciences?

Summary

How does Anavex Life Sciences compare to Calliditas Therapeutics AB (publ)?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL vs. The Competition

Anavex Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anavex Life Sciences (AVXL) Competitors

AVXL vs. QURE, MLTX, PHAR, JBIO, and CALT

How does Anavex Life Sciences compare to uniQure?

Which has better valuation and earnings, QURE or AVXL?

Is QURE or AVXL more profitable?

Do insiders & institutionals hold more shares of QURE or AVXL?

Does the media refer more to QURE or AVXL?

Which has more risk & volatility, QURE or AVXL?

Do analysts recommend QURE or AVXL?

Summary

How does Anavex Life Sciences compare to MoonLake Immunotherapeutics?

Do institutionals & insiders hold more shares of AVXL or MLTX?

Does the media refer more to AVXL or MLTX?

Which has preferable valuation & earnings, AVXL or MLTX?

Do analysts recommend AVXL or MLTX?

Is AVXL or MLTX more profitable?

Which has more volatility and risk, AVXL or MLTX?

Summary

How does Anavex Life Sciences compare to Pharming Group?

Do analysts recommend AVXL or PHAR?

Do institutionals & insiders hold more shares of AVXL or PHAR?

Is AVXL or PHAR more profitable?

Does the media refer more to AVXL or PHAR?

Which has preferable valuation & earnings, AVXL or PHAR?

Which has more volatility and risk, AVXL or PHAR?

Summary

How does Anavex Life Sciences compare to Jade Biosciences?

Do analysts rate JBIO or AVXL?

Is JBIO or AVXL more profitable?

Does the media prefer JBIO or AVXL?

Which has higher earnings and valuation, JBIO or AVXL?

Do insiders and institutionals hold more shares of JBIO or AVXL?

Which has more risk & volatility, JBIO or AVXL?

Summary

How does Anavex Life Sciences compare to Calliditas Therapeutics AB (publ)?

Which has preferable valuation and earnings, CALT or AVXL?

Do institutionals and insiders believe in CALT or AVXL?

Is CALT or AVXL more profitable?

Does the media favor CALT or AVXL?

Do analysts rate CALT or AVXL?

Which has more volatility & risk, CALT or AVXL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL vs. The Competition

Anavex Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools